The Journal of Headache and Pain 2024 Apr 26;25(1):68. doi: 10.1186/s10194-024-01770-x. Phuong Thao Tran, Maryse Lapeyre-Mestre, Baricault Berangere, Michel Lanteri-Minet, Aurore Palmaro, Anne Donnet, Joëlle Micallef Abstract Background: Several studies have focused on the use of triptan and the risk of acute vascular events but the
Patient Sex in Prescribing CGRP Receptor Antagonists for Migraine
JAMA Neurology JAMA Neurol. Published online February 26, 2024. doi:10.1001/jamaneurol.2023.5835 Michel Lanteri-Minet; Shuu-Jiun Wang; Paolo Martelletti To the Editor In a recent JAMA Neurology Viewpoint,1 Porreca and Dodick raised an important issue by discussing gender differences in outcomes of calcitonin
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial
The Lancet Neurology 2024 Feb 13:S1474-4422(24)00025-5. doi: 10.1016/S1474-4422(24)00025-5. Cristina Tassorelli, Krisztián Nagy, Patricia Pozo-Rosich, Michel Lanteri-Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M Trugman Abstract Background: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of
Generalizability of clinical trial efficacy results to a real-world population: An example in migraine prevention
The Journal of managed care and specialty pharmacy 2023 Dec;29(12):1321-1330.doi: 10.18553/jmcp.2023.29.12.1321. Marie-Ange Paget, Antje Tockhorn-Heidenreich, Mark Belger, Florence Chartier, Michel Lantéri-Minet Abstract Background: Health care decision makers are often concerned about the external validity of randomized controlled trials (RCTs), as their results may not
One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study
The Journal of Headache and Pain 2023 Nov 8;24(1):152. doi: 10.1186/s10194-023-01680-4. M Lanteri-Minet, R Fabre, C Martin, K Pradat, A Alchaar, E Bozzolo, M L Duchene, E K Van Obberghen, A Donnet, D Fontaine Abstract Background: Randomized clinical trials have
Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study
The Journal of Headache and Pain 2023 Nov 8;24(1):151. doi: 10.1186/s10194-023-01683-1. Richard B Lipton, Michel Lanteri-Minet, Elizabeth Leroux, Aubrey Manack Adams, Janette Contreras-De Lama, Michael L Reed, Kristina M Fanning, Dawn C Buse Abstract Background: Individuals with migraine frequently experience pre- and post-headache symptoms. This analysis aimed
The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2023 Sep;20(5):1305-1315.doi: 10.1007/s13311-023-01404-1. Epub 2023 Jul 12. Diane Merino, Alexandre O Gérard, Elise K Van Obberghen, Alexandre Destere, Michel Lanteri-Minet, Milou-Daniel Drici Abstract Migraine constitutes the world’s second-leading cause of disability. Triptans, as
Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care
Cephalalgia 2023 Jun;43(6):3331024231180611.doi: 10.1177/03331024231180611. Aubrey Manack Adams, Dawn C Buse, Elizabeth Leroux, Michel Lanteri-Minet, Fumihiko Sakai, Manjit S Matharu, Zaza Katsarava, Michael L Reed, Kristina Fanning, Katherine Sommer, Richard B Lipton Abstract Background: The Chronic Migraine Epidemiology and Outcomes-International study provides insight into people with migraine in multiple countries. Methods:
Radiosurgery for classical trigeminal neuralgia: impact of the shot size on clinical outcome
The Journal of Headache and Pain 2023 May 11;24(1):51.doi: 10.1186/s10194-023-01583-4. Cécile Ortholan, Philippe Colin, Benjamin Serrano , Thibault Bouet, Nicolas Garnier, Maud le Guyader, Regis Amblard, Rémy Villeneuve, Stéphane Chanalet, Haiel Alchaar, Eric Bozzolo, Michel Lanteri-Minet, Denys Fontaine Abstract Background: This study compares the outcome of patients suffering from medically refractory classical
Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study
Cephalalgia 2023 May;43(5):3331024231170807.doi: 10.1177/03331024231170807. Messoud Ashina, Michel Lanteri-Minet, Anders Ettrup, Cecilie Laurberg Christoffersen, Mette Krog Josiassen, Ravinder Phul, Bjørn Sperling, Patricia Pozo-Rosich Abstract Background: Migraine is a disabling neurological disease adversely affecting many aspects of life. Most patients are still required to have failed several older oral